Clinical trials: Empagliflozin
Diabetes Mellitus, Type 2, Healthy
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
- Trial name
- NCT01867307
- Testing
- Empagliflozin, BI 10773
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if…
- Trial name
- NCT06766500
- Testing
- Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets, Synjardy® 5 mg/850 mg film-coated tablets
- Where
- Russia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Type 2 Diabetes
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
In normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production.
- Trial name
- NCT02792400
- Testing
- LY2403021, Standardised liquid meal, Linagliptin
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Prediabetes
Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes.
- Trial name
- PREVNT (NCT06828731)
- Testing
- Empagliflozin 10mg daily, Lifestyle education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Charles George VA Medical Center
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection…
- Trial name
- NCT03448406
- Testing
- Empagliflozin
- Where
- 108 sites in United States, Australia and 9 more
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Diabetic Kidney Disease
Treatment of Patients With Diabetic Kidney Disease
Due to irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns.
- Trial name
- NCT06187493
- Testing
- lisinopril, enalapril, dapagliflozin, empagliflozin
- Volunteers
- 70 people
- Sponsor
- Assiut University
Heart Failure
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
the study to investigate the efficacy of empagiflozin in pediatric heart failure
- Trial name
- NCT07692256
- Testing
- Empagliflozin (EMPA), Standard medical treatment
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Diabetes Mellitus, Type 2
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants…
- Trial name
- PIONEER START (NCT05444153)
- Testing
- Semaglutide, Empagliflozin
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes Mellitus
Empagliflozin Effect on Glucose Toxicity
Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study
- Trial name
- NCT03437330
- Testing
- Empagliflozin (Jardiance®), Insulin Glargine (Lantus®)
- Where
- 2 sites in Germany
- Sponsor
- University Hospital Tuebingen
Diabetes Mellitus, Type 2
JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT02848833
- Testing
- JARDIANCE 10mg, JARDIANCE 25mg
- Where
- South Korea
- Volunteers
- 3,368 people
- Sponsor
- Boehringer Ingelheim
Vascular Stiffness, Hypoglycemic Agents
The Effects of Empagliflozin on Arterial Wall Characteristics
Introduction: Diabetes mellitus is characterized by impaired arterial function and high incidence of cardiovascular events. Metformin and most recent antidiabetic groups of drugs, SGLT2 inhibitors, were in previous studies shown…
- Conditions
- Vascular Stiffness, Hypoglycemic Agents, Diabetes Complications, Diabetes Mellitus, Type 1
- Trial name
- NCT03639545
- Testing
- Empagliflozin 25mg, Metformin, Empagliflozin/Metformin
- Where
- Slovenia
- Volunteers
- 120 people
- Sponsor
- University Medical Centre Ljubljana
Heart Failure, Anemia
Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure
This retrospective cohort study investigates the effects of SGLT2 inhibitor therapy on erythropoiesis and its association with cardiac and renal outcomes in patients with chronic heart failure.
- Conditions
- Heart Failure, Anemia, Renal Insufficiency
- Trial name
- SGLT2-RISE (NCT07478575)
- Where
- Slovenia
- Volunteers
- 85 people
- Sponsor
- University Medical Centre Ljubljana
Type 2 Diabetes
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
This study aims to compare the effect of two drugs used to treat diabetes, that is, Dapagliflozin and Empagliflozin on HbA1c (which is an indicator of blood sugar over the last 3 months) body weight, liver and kidney function…
- Trial name
- NCT07311551
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Empagliflozin (25 Mg Tab) along with standard medical therapy
- Volunteers
- 112 people
- Sponsor
- Bhavya Bhavya, MD
Obstructive Sleep Apnea (OSA), Sleep Apnea Syndrome, Obstructive
Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.
The goal of this randomized clinical trial was to evaluate the effects of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i) on sleep and cardiac outcomes in adults with heart failure (HF) and obstructive sleep…
- Conditions
- Obstructive Sleep Apnea (OSA), Sleep Apnea Syndrome, Obstructive, Heart Failure
- Trial name
- HF(L)OSA (NCT07556094)
- Testing
- Empagliflozin, Continuous Positive Airway Pressure (CPAP)
- Where
- Poland
- Volunteers
- 70 people
- Sponsor
- Medical University of Bialystok
Healthy Subjects
Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- NCT06232239
- Testing
- Empagliflozin-Test product, Empagliflozin-Reference product
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Type 2 Diabetes Mellitus
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
gemigliptin,SGLT-2i DDI study
- Trial name
- NCT03565458
- Testing
- Gemigliptin, Dapagliflozin, Empagliflozin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection
Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk
The SGLT2 inhibitors have changed the treatment of type 2 diabetes mellitus in recent years, especially in patients with cardiovascular or renal disease.
- Trial name
- NCT05520684
- Testing
- urine culture and urinalysis
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Trabzon Arakli Bayram Halil Public Hospital
Diabetes Mellitus, Type 2, Arterial Hypertension
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.
- Conditions
- Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes
- Trial name
- GliRACo1 (NCT03917758)
- Testing
- SGLT2 inhibitor
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII).
- Trial name
- NCT02414958
- Testing
- Empagliflozin
- Where
- 131 sites in United States, Australia and 15 more
- Volunteers
- 730 people
- Sponsor
- Boehringer Ingelheim